[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Gibraltar, vaccine failure", "description": "Gibraltar\n\nPopulation, 33,691\n\nHas administered at least 94,469 vaccine doses\n\nEnough to have fully vaccinated 140.2% of the country\u2019s population. \n\nFace masks required in all shops and supermarkets, public transport, in medical centres, indoor funerals, Airport.\n\nhttps://www.worldometers.info/coronavirus/country/gibraltar/\n\nEurope\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019\n\nWorld Health Organization\n\nEurope remains \u201cin the firm grip\u201d\n\nDeath toll could top 2.2 million this winter\n\nAnother 700,000 deaths by March 1\n\nhigh or extreme stress in intensive care units (ICUs) in 49 out of 53 countries between now and March 1, 2022\n\nDirector for WHO Europe, Hans Kluge\n\nface a challenging winter ahead\n\nvaccine plus\n\nFace masks reduce COVID incidence \nby 53 %\n\nOver 160,000 deaths could be prevented (by March 1) if universal mask coverage of 95%\n\n\nPascal Soriot, the chief executive of AstraZeneca\n\nhttps://www.telegraph.co.uk/news/2021/11/23/astrazeneca-jab-could-reason-britain-faring-better-europe-says/\n\nUK not seeing so many hospitalisations relative to Europe despite a high number of cases.\n\nLong term T cell immunity after antibodies wane\n\nLooks like, AstraZeneca initially gives higher levels of T-cells\n\nFrance, Germany, Spain, Belgium \u2013 restricted AZ to the under 65s\n\nUK may have high T cells from natural infection and cross immunity from other coronavirus infections\n\nGovernment source\n\nEuropean leaders had all these unfounded concerns about AstraZeneca and its use in older people\n\nIf you look at the data, you can see us using it early has been incredibly helpful in terms of protecting older and vulnerable people from this disease for longer\n\nDr Peter English\n\nPeople whose immune systems have produced a strong T-cell response but a weaker antibody response might be more likely to be infected in the first place \n\nbut more likely to be able to fight the infection, and they will be much less likely to develop severe disease\n\nIt is plausible that this generated an excellent T-cell response, which means that while people can still be infected and infectious, they are unlikely to be seriously unwell\n\nProf Matthew Snape, Oxford University\n\nThe best T-cell responses seem to come if you give a first dose of the AstraZeneca vaccine followed by Pfizer\n\nProf Dame Sarah Gilbert\n\nThird jabs may be unnecessary\n\nUK\n\nhttps://coronavirus.data.gov.uk\n\nUS\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html\n\nCenters for Disease Control and Prevention Director Rochelle Walensky\n\nSeven-day average\n\nCases up 18%\n\nHospital admissions up 6%\n\n135 million people eligible for boosters\n\nHeading into the winter months, when respiratory viruses are more likely to spread,\n \nand with plans for increased holiday season travel and gatherings, \n\nboosting people\u2019s overall protection against covid-19 disease and death was important to do now\n\nIn the fully vaccinated\n\nhttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html\n\nInfections happen in only a small proportion of people who are fully vaccinated, even with the Delta variant. \n\nWhen these infections occur among vaccinated people, they tend to be mild\n\nIf you are fully vaccinated and become infected with the Delta variant, you can spread the virus to others\n\nDr Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases\n\nhttps://www.businessinsider.com/fauci-babies-toddlers-should-get-covid-19-vaccines-by-spring-2021-11\n\nNext spring\n\nPfizer trial ongoing\n\n6 months to 5 years\n\nModerna and Johnson & Johnson, have pediatric vaccine trials planned\n\nEmergency use authorization to the Food and Drug Administration\n\nCanada\n\nhttps://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html\n\nHealth Canada\n\nPfizer-BioNTech Comirnaty, in children 5 to 11 years\n\n(12 to 15s, May 5, 2021)\n\nthe Department has determined that the benefits of this vaccine for children between 5 and 11 years of age outweigh the risks\n\nTwo-dose regimen, 10 micrograms\n\nThree weeks apart\n\nImmune response in children 5 to 11 years, comparable to 16 to 25\n\nThe vaccine was 90.7% effective at preventing COVID-19 in children 5 to 11 years of age\n\nand no serious side effects were identified\n\nOngoing studies and real-world data\n\nto ensure that the benefits of the vaccine continue to outweigh any risks, as well as to detect any potential new safety signals in any age group", "link": "https://www.youtube.com/watch?v=z1eQw7x6D1E", "date_published": "2021-11-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]